CD137

CD137, a constituent of the tumor necrosis factor receptor superfamily, is a
promising target for augmenting anticancer immune responses. CD137 activities in T
cells encompass the regulation of activation, proliferation, and apoptosis. CD137
facilitates the regulation of the activation of several immune cells, including CD4(+) T
cells, CD8(+) T cells, dendritic cells, and natural killer cells. Recent studies
demonstrate that the anticancer efficacy of therapeutic tumor-targeting antibodies
can be enhanced by including agonistic antibodies that target CD137. Ligation of
CD137 delivers a costimulatory signal across many immune cell subsets, indicating
that CD137 antibodies may enhance cancer therapy and have been associated with
breast cancer, melanoma, and lymphoma. Consequently, CD137 agonists signify a
viable immunotherapeutic strategy for cancer treatment.

Specifications